Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?
Alessandro LucchesiSilvia CarloniSerena De MatteisMartina GhettiGerardo MusuracaMonica PoggiaspallaAccursio F AugelloGiulio GiordanoPier P FattoriGiovanni MartinelliRoberta NapolitanoPublished in: British journal of haematology (2019)
This study was conducted to evaluate the expression of fibrinogen receptors on platelets of Philadelphia-negative chronic myeloproliferative neoplasm (MPN) patients. We collected blood samples from 40 consecutive MPN patients and healthy volunteers. We performed flow cytometry analysis of P-selectin expression and integrin beta-3, activation of glycoprotein (GP) IIb/IIIa and fibrinogen receptor exposure (PAC-1 binding). Surprisingly, we found a very low PAC-1 binding capacity in MPN patients; however, the expression of PAC-1 was almost completely recovered with aspirin intake. We hypothesize that the hypercoagulable states observed in MPN patients could depend on a primarily plasma-driven impairment of fibrin turnover and thrombin generation.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- binding protein
- acute lymphoblastic leukemia
- physical activity
- cardiovascular disease
- patient reported outcomes
- atrial fibrillation
- body mass index
- transcription factor
- long non coding rna
- low grade
- high grade
- patient reported
- dna binding